Kunkel Lori Anne 4
4 · Oric Pharmaceuticals, Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Kunkel Lori Anne
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-03-03−20,500→ 0 totalExercise: $6.33From: 2024-06-11Exp: 2033-06-13→ Common Stock (20,500 underlying) - Exercise/Conversion
Common Stock
2025-03-03$3.75/sh+27,666$103,748→ 48,166 total - Exercise/Conversion
Common Stock
2025-03-03$6.33/sh+20,500$129,765→ 68,666 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-03−27,666→ 5,534 totalExercise: $3.75Exp: 2032-06-16→ Common Stock (27,666 underlying)
Footnotes (1)
- [F1](A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022.